ARTICLE | Clinical News
Tamatinib fosdium: Phase II started
March 23, 2009 7:00 AM UTC
Rigel began an open-label, North American Phase II trial to evaluate 200 mg of oral R788 given twice daily for at least 8 weeks or until disease progression. The first stage will enroll 19 patients wh...